Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 Next >
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Aegis Virtual Conference on February 24, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides 2021 Year End Summary
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.